

INDEPENDENT AUDITOR'S REPORT

To,

The Members of

Kopran Laboratories Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Kopran Laboratories Limited ("the Company"), which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2023, and its profit and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.



Information Other than the Financial Statements and Auditor's Report thereon

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the financial statements and our auditor's report thereon. The Annual Report is expected to be made available to us after the date of this auditor's report. Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether such other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. When we read the annual report, if, based on the work we have performed, we conclude that there is a material misstatement therein, we are required to report that fact and communicate the matter to those charged with governance.

Responsibilities of Management for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards (AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2(A) As required by Section 143(3) of the Act, based on our audit we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the AS specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the Directors as on March 31, 2023 and taken on record by the Board of Directors, none of the Directors is disqualified as on March 31, 2023 from being appointed as a Director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" to this Report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting, of the Company.
- g) With respect to the other matters to be included in the Auditors' Report in accordance with the requirements of section 197(16) of the Act as amended:



In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act.

- h) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
- i) The Company has disclosed the impact of pending litigations as at March 31, 2023 on its financial position in its financial statements - Refer Note No. 27 and 37(i) to the financial statements;
 - ii) The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts - Refer Note No. 37(ii) to the financial statements;
 - iii) There were no amounts, which were required to be transferred to the Investor Education and Protection Fund by the Company during the year - Refer Note No. 37(iii) to the financial statements.
 - iv) a) The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entities (Intermediaries), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the ultimate beneficiaries.
 - b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entities (Funding Parties), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or provide any guarantee, security or the like on behalf of the ultimate beneficiaries.



- c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under Sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
- (v) The Company has not declared or paid any dividend during the year and as such the compliance of section 123 of the Act has not been commented upon.
- (vi) Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the Company with effect from April 01, 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended March 31, 2023.

For Khandelwal Jain & Co.,
Chartered Accountants

Firm Registration No.: 105049W



S. S. Shah

Partner

Membership Number: 033632

UDIN: 23033632BGXWIX7290



Place: Mumbai

Date : September 04, 2023

Annexure "A" to the Independent Auditors' Report

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date to the Members of Kopran Laboratories Limited on the financial statements for the year ended March 31, 2023)

In terms of the information and explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- i) (a) In respect of the Property, Plant and Equipment and intangible assets of the Company:-
 - (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
 - (B) The Company does not have any Intangible assets.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the fixed assets, except for the equipments lying with the third parties, were physically verified during the year by the Management in accordance with a regular programme of verification which provides for physical verification of all the fixed assets at reasonable intervals. For equipments lying with third parties at the year end, confirmations have been called for and the evidence of receipt of service charges has been linked with fixed assets records. According to the information and explanations given to us, no material discrepancies were noticed on such verification. In our opinion, the periodicity of physical verification is reasonable having regard to the size of the company and nature of its assets.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company does not have any immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee). Accordingly, clause 3(i)(c) of the Order is not applicable



- (d) The Company has not revalued any of its Property, Plant and Equipment during the year.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or are pending against the Company as at March 31, 2023 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and Rules made thereunder.
- ii) (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and the coverage as followed by management were appropriate. No discrepancies were noticed on such verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventories.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion, the differences between the quarterly returns or statements (comprising stock statements, book debt statements and other stipulated financial information) filed by the Company with such banks or financial institutions and the books of account of the Company were not material (Refer Note No. 38(vi) of the financial statements).
- iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has granted loans, secured or unsecured. The Company has not made investments or provided any advances in the nature of loans or guarantee or security, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties.
- (a) (A) Based on the audit procedures carried out by us and as per the information and explanations given to us, the Company does not have any subsidiaries, associates or joint ventures.
- (B) The Company has provided loans to parties other than subsidiaries, joint ventures and associates as under.

Particulars	Amount (Rs in Lakhs)
<u>Loan to others</u>	
Loans given during the year	150.00
Balance as at the year end	100.00
Maximum amount outstanding at any time during the year	150.00



- (b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the terms and conditions of the loans given are, prima facie, not prejudicial to the interest of the Company.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in the case of loans given, the schedule of repayment of principal and payment of interest has been stipulated and the repayments and receipts are regular.
- (d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no overdue amount for more than ninety days in respect of loans given.
- (e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan given falling due during the year, which has been renewed or extended or fresh loans given to settle the overdues of existing loans given to the same party.
- (f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted loans which are either repayable on demand or without specifying any terms or period of repayment.
- iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Companies Act, 2013 and the Company has not provided any guarantee or security as specified under Section 186 of the Companies Act, 2013. Further, the Company has complied with the provisions of Section 186 of the Companies Act, 2013 in relation to loans given during the year and investments made.
- v) According to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits during the year from the public within the meaning of section 73 to 76 of the Act and rules framed thereunder. Accordingly, clause 3(v) of the Order is not applicable.
- vi) According to information and explanations given to us, the maintenance of cost records has not been specified by the Central Government under section 148(1) of the Act for the business activities carried out by the Company and hence, reporting under paragraph 3(vi) of the Order is not applicable to the Company.



- vii) (a) According to the information and explanations given to us and records examined by us, the Company is generally regular in depositing undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, duty of customs, Cess, and any other material statutory dues, as applicable to it, with the appropriate authorities.
- (b) According to information and explanations given to us, there were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Goods and Service Tax, duty of Customs, Cess, and other material statutory dues in arrears as at March 31, 2023 for a period of more than six months from the date they became payable.
- (c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no dues with respect to Goods and Service Tax, Provident Fund, Employees' State Insurance, Income-tax or Cess which have not been deposited as on March 31, 2023 on account of any dispute.
- viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
- ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans or other borrowings or in payment of interest thereon to any lender.
- (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.
- (c) In our opinion and according to the information and explanations given to us, the Company has utilized the money obtained by way of term loans during the year for the purposes for which they were obtained.
- (d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long term purposes by the Company.



- (e) According to the information and explanations given to us, the Company does not have any subsidiaries, associates or joint ventures. Accordingly, clause 3(ix)(e) of the Order is not applicable.
- (f) According to the information and explanations given to us, the Company does not have any subsidiaries, associates or joint ventures. Accordingly, clause 3(ix)(f) of the Order is not applicable.
- x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.
- (b) The Company has not made any preferential allotment or private placement of shares / fully or partially or optionally convertible debentures during the year under audit. Accordingly, clause 3(x)(b) of the Order is not applicable.
- xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.
- (b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the Management, there are no whistle blower complaints received by the Company during the year.
- xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Sections 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable Accounting Standards.



- xiv) In our opinion and according to the information and explanations given to us, requirement of Internal Audit as per section 138 of Companies Act is not applicable to Company and hence, reporting under paragraph 3(xiv)(a) and (b) of the said Order is not applicable to the Company..
- xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.
- xvi)(a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.
- (b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.
- (c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.
- (d) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.
- xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.
- xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.
- xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.



- xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For Khandelwal Jain & Co.,

Chartered Accountants

Firm Registration No.: 105049W



S. S. Shah

Partner

Membership Number: 033632

UDIN: 23033632BGXWIX7290



Place: Mumbai

Date : September 04, 2023

Annexure "B" to the Independent Auditors' Report

(Referred to in paragraph 2A(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date to the Members of Kopran Laboratories Limited on the financial statements for the year ended March 31, 2023)

Report on the Internal Financial Controls Over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

We have audited the internal financial controls over financial reporting of **Kopran Laboratories Limited** ("the Company") as of March 31, 2023 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Control over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting with reference to the financial statements based on our audit. We conducted our audit in accordance with the Guidance Note on audit of Internal Financial Controls over Financial Reporting ("the Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI") and the Standards on Auditing as specified under Section 143 (10) of the Act, to the extent applicable to an audit of internal financial controls. Those standards and the Guidance



Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls over financial reporting with reference to the financial statements.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting with reference to the financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with the generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.



Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting with reference to the financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to the financial statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to the financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls over financial reporting with reference to these financial statements and such internal financial controls over financial reporting with reference to these financial statements were operating effectively as at March 31, 2023, based on the criteria for internal control over financial reporting established by the Company considering the essential components of internal controls stated in the Guidance Note issued by ICAI.

For Khandelwal Jain & Co.,

Chartered Accountants

Firm Registration No.: 105049W



S. S. Shah

Partner

Membership Number: 033632

UDIN: 23033632BGXWIX7290



Place: Mumbai

Date : September 04, 2023

KOPRAN LABORATORIES LIMITED
BALANCE SHEET AS AT MARCH 31, 2023

Amount in lakhs


Particulars	Note No.	March 31, 2023	March 31, 2022
EQUITY AND LIABILITIES			
Shareholder's Funds			
Share capital	2	150.00	150.00
Reserves and surplus	3	3,768.13	2,841.82
Non - current liabilities			
Long - term borrowings	4	716.27	703.10
Long - term provisions	5	119.94	126.77
Deferred tax liabilities (net)	12	64.72	-
Current liabilities			
Short - term borrowings	6	947.69	298.85
Trade payables	7		
(i) Total outstanding dues to micro enterprises and small enterprises		-	2.50
(ii) Total outstanding dues to creditors other than micro enterprises and small enterprises		1,045.32	766.77
Other current liabilities	8	284.36	228.66
Short-term provisions	9	70.59	67.48
Total		7,167.02	5,185.95
Assets			
Non - current assets			
Property, plant and equipment	10	2,583.88	1,788.42
Non current investments	11	19.35	19.35
Deferred tax assets (net)	12	-	74.11
Other non-current assets	13	404.11	404.59
Current assets			
Inventories	14	920.69	954.25
Trade receivables	15	1,850.87	940.72
Cash and bank balances	16	783.01	634.73
Short - term loans and advances	17	351.11	269.33
Other current assets	18	254.00	100.44
Total		7,167.02	5,185.95

Significant accounting policies and Notes forming part of the financial statements

1 to 39


As per our report of even date
For Khandelwal Jain & Co.
Chartered Accountants
Firm Registration No. - 105049W

For and on behalf of the Board of Directors


S.S. Shah
PARTNER
Membership No. 033632




VARUN SOMANI
MANAGING DIRECTOR
DIN No. 00015384


NAMRATA SOMANI
DIRECTOR
DIN No. 07095595

Place : Mumbai
Date : 04/09/2023

KOPRAN LABORATORIES LIMITED
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023

Amount in lakhs

Particulars	Note No.	For the Year Ended	
		March 31, 2023	March 31, 2022
INCOME			
Revenue from operations	19	7,056.96	5,386.88
Other income	20	67.76	60.68
Total income		7,124.72	5,447.56
EXPENDITURE			
Purchase of stock-in-trade	21	3,399.35	2,999.88
Changes in inventories of finished goods, work-in-progress and Stock-in-trade	22	33.56	(137.81)
Employee benefit expense	23	861.77	760.53
Financial costs	24	127.10	115.71
Depreciation and amortization expense	11	218.30	151.44
Other expenses	25	1,084.50	817.36
Total expenses		5,724.58	4,707.11
Profit before tax		1,400.14	740.45
Tax expense			
Current tax		335.00	161.00
Deferred tax	12	28.31	(21.68)
Tax impact of earlier years		110.52	-
Profit after tax		926.31	601.13
Earning per equity share: (Face Value of Rs. 10 each)			
Basic and Diluted	26	46.32	30.06
Significant accounting policies and Notes forming part of the financial statements	1 to 39		

As per our report of even date

For Khandelwal Jain & Co.

Chartered Accountants

Firm Registration No. - 105049W

S.S.H.

S.S. Shah

PARTNER

Membership No. 033632



For and on behalf of the Board of Directors

[Signature]

VARUN SOMANI
MANAGING DIRECTOR
DIN No. 00015384

N. Somani

NAMRATA SOMANI
DIRECTOR
DIN No. 07095595

Place : Mumbai

Date : 04/09/2023

KOPRAN LABORATORIES LIMITED
CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2023

Particulars	Amount in lakhs	
	March 31, 2023	March 31, 2022
A. Cash Flows from Operating Activities		
Profit before tax	1,400.14	740.45
Adjustments for:		
Depreciation	218.29	151.44
Finance cost	127.10	115.71
Interest income	(44.12)	(25.28)
Profit on sale of fixed assets	(1.54)	-
Operating Cash Flows before Working Capital Adjustments	1,699.87	982.32
Adjustments for:		
Decrease in long term provision	(6.83)	(7.15)
Increase in trade payables	276.05	160.12
Increase in other current liabilities	57.88	64.15
Increase in short-term provisions	3.12	12.44
Decrease / (Increase) in other non-current assets	0.48	(0.29)
Decrease / (Increase) in inventories	33.56	(137.82)
Increase in trade receivables	(910.15)	(134.30)
Increase in short-term loans & advances	(81.78)	(25.04)
(Increase) / Decrease in other current assets	(153.57)	20.74
Cash Generated from Operations	918.63	935.17
Direct taxes paid	(337.18)	(139.22)
Net Cash Flows from Operating Activities	581.45	795.95
B. Cash Flows from Investing Activities		
Interest income	44.12	25.28
Purchase of fixed assets	(1,017.91)	(621.01)
Proceeds from Sale of fixed assets	5.70	-
Bank balance other than cash and cash equivalent below	30.00	(400.00)
Net Cash Flows from Investing Activities	(938.09)	(995.73)
C. Cash Flows from Financing Activities		
Finance Cost	(127.10)	(115.71)
Proceeds/(repayment) of short term borrowings	328.84	67.75
Proceeds from long term borrowings	865.96	565.41
Repayment of long term borrowings	(419.79)	(468.94)
Proceeds/(repayment) of loan from directors	(113.00)	(15.50)
Net Cash Flows from Financing Activities	534.91	33.01
Net Increase/(Decrease) in Cash & Cash Equivalents	178.27	(166.78)
Cash & Cash Equivalents		
As at the beginning of the year	22.19	188.96
As at the end of the year	200.46	22.19
Net Increase/(Decrease) in Cash & Cash Equivalents	178.27	(166.78)


Significant accounting policies and Notes forming part of the financial statements

1 to 39

As per our report of even date
For Khandelwal Jain & Co.
Chartered Accountants
Firm Registration No. - 105049W

S.S.H.

S.S. Shah
PARTNER
Membership No. 033632



For and on behalf of the Board of Directors

[Signature]

VARUN SOMANI
MANAGING DIRECTOR
DIN No. 00015384

[Signature]

NAMRATA SOMANI
DIRECTOR
DIN No. 07095595

Place : Mumbai
Date : 04/09/2023

KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2) Share capital

Particulars	As at March 31, 2023		As at March 31, 2022	
	in Nos.	Amount in lakhs	in Nos.	Amount in lakhs
Authorised				
Equity shares of Rs. 10/ each	2,000,000	200.00	2,000,000	200.00
	2,000,000	200.00	2,000,000	200.00
Issued, Subscribed & Paid up				
Equity shares of Rs. 10/ each fully paid up	1,500,000	150.00	1,500,000	150.00
	1,500,000	150.00	1,500,000	150.00

2.1) Reconciliation of Number of Shares

Particulars	As at	As at
	March 31, 2023	March 31, 2022
	in Nos.	in Nos.
Opening Balance	1,500,000	1,500,000
Add: Shares issued During the period	-	-
Less: Shares forfeited	-	-
Closing Balance	1,500,000	1,500,000

2.2) Rights, Preferences and Restrictions attached to Shares

As to Dividend

The Shareholders are entitled to receive dividend in proportion to the amount of paid up equity shares held by them. The Company has not declared any dividend during the period.

As to Repayment of capital

In the event of liquidation of the Company, the holders of equity shares are entitled to receive the remaining assets of the Company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.

As to Voting

The Company has only one class of shares referred to as equity shares having a face value of Rs.10. Each holder of the equity share is entitled to one vote per share.

2.3) Shares held by Holding / Ultimate Holding Company and / or their Subsidiaries / Associates

There is no Holding Company or Ultimate Holding Company of the Company. Accordingly, disclosures pertaining to shares of the Company held by held by holding company or its ultimate holding company including shares held by subsidiaries or associates of the holding company or the ultimate holding company is not applicable.

2.4) Details of Shareholders holding more than 5% Shares in the Company

Shareholders Name	As at March 31, 2023		As at March 31, 2022	
	No. of Shares	% holding	No. of Shares	% holding
Oriental Enterprises	319,500	21.30%	319,500	21.30%
Kopran Lifestyle Ltd.	280,200	18.68%	280,200	18.68%
(Formerly known as Ridhi Sidhi Equif.Ltd.)				
Sarvamangal Mercantile Co. Ltd.	84,000	5.60%	84,000	5.60%
Meenul Metallizing Pvt.Ltd.	287,700	19.18%	287,700	19.18%
Sorabh Trading Pvt. Ltd.	240,300	16.02%	240,300	16.02%

2.5) Details of shareholding of promoters

Promoter Name	As at March 31, 2023		As at March 31, 2022	
	No. of Shares	% holding	No. of Shares	% holding
Sarvamangal Mercantile Co. Ltd.	84,000	5.60%	84,000	5.60%
Oriental Enterprises	319,500	21.30%	319,500	21.30%
Meenul Metallizing Pvt.Ltd.	287,700	19.18%	287,700	19.18%
Suhrid Susheel Somani	6,450	0.43%	6,450	0.43%
Kopran Lifestyle Ltd.	280,200	18.68%	280,200	18.68%
(Formerly known as Ridhi Sidhi Equif.Ltd.)				
Bottle Closure India Pvt. Ltd.	24,000	1.60%	24,000	1.60%
Sorabh Trading Pvt. Ltd.	240,300	16.02%	240,300	16.02%
G.Claridge & Company Ltd.	60,000	4.00%	60,000	4.00%
Vandana Somani	9,630	0.64%	9,630	0.64%
Mr Adarsh Somani	9,660	0.64%	9,660	0.64%
S. K. Somani & Co.	35,100	2.34%	35,100	2.34%
Skyland Securities Pvt. Ltd.	37,200	2.48%	37,200	2.48%
Bigflex Enterprises Pvt. Ltd.	30,000	2.00%	30,000	2.00%

3) Reserves and surplus

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
Surplus in Statement of Profit and Loss		
Opening Balance	2,841.82	2,240.69
Add: Profit for the year as per Statement of Profit and Loss	926.31	601.13
Less: Appropriation during the year, if any		
Total	3,768.13	2,841.82



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

4) Long - term borrowings

Particulars	(Amount in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Secured		
From Banks - Term loan for equipment		
- Yes Bank Limited	65.13	217.58
- Central Bank of India	-	52.52
- Indusind Bank Limited	607.04	-
From others - Vehicle Loan	44.10	-
Unsecured, repayable on demand		
Loan from Directors	-	433.00
Total	716.27	703.10

4.1) a) Term loan for equipment from Yes Bank Limited is secured by way of hypothecation of Medical Equipments

Rate of Interest - 10.16% p.a

Terms of Repayment are as under:

March 31, 2024 - Rs. 152.45 Lakhs

March 31, 2025 - Rs. 65.13 Lakhs

b) Term loan for equipment from Central Bank of India (CBI) is secured by way of hypothecation of Medical Equipments

Rate of Interest - 7.70 % p.a. to 9.80 % p.a.

Terms of Repayment are as under:

March 31, 2024 - Rs. 54.39 Lakhs

c) Term Loan for Equipment from Indusind Bank Limited is secured by way of hypothecation of Medical Equipments

Rate of Interest - 8.50% p.a. to 9.51% p.a.

Terms of Repayment are as under:

March 31, 2024 - Rs. 324.99 Lakhs

March 31, 2025 - Rs. 361.48 Lakhs

March 31, 2026 - Rs. 238.89 Lakhs

March 31, 2027 - Rs. 6.67 Lakhs

d) Vehicle Loan from MBFS India Private Limited are secured by way of hypothecation of vehicle

Rate of Interest - 7.95% p.a

Terms of Repayment are as under:

March 31, 2024 - Rs. 21.48 Lakhs

March 31, 2025 - Rs. 23.26 Lakhs

March 31, 2026 - Rs. 20.84 Lakhs

5) Long - term provisions

Particulars	(Amount in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Provision for Employee Benefits		
Gratuity (Refer Note 29)	73.73	83.67
Leave encashment (Refer Note 29)	46.21	43.10
Total	119.94	126.77

6) Short Term Borrowings

Particulars	(Amount in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Secured		
Cash Credit from CBI	74.38	1.40
Current Maturities of Long-term Borrowings (for Security, rate of interest and terms of repayment Refer Note 4.1 above)	553.31	297.45
Unsecured, repayable on demand		
Loan from Directors	320.00	-
Total	947.69	298.85

6.1) Cash credit facility availed from CBI is secured by hypothecation of stock & book debts (present & future), Collateral Security by mortgage of Vishal Investment Gala No.307,308,409 and personal guaranteed by directors/ promoters jointly and severally.

Rate of Interest on cash credit - 7.70 % p.a. to 9.80 % p.a.



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

7) Trade payables

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
Trade Payables (including Acceptances)		
(i) Total outstanding dues to micro enterprises and small enterprises (Refer Note "A" below)	-	2.50
(ii) Total outstanding dues to creditors other than micro enterprises and small enterprises	1,045.32	766.77
Total	1,045.32	769.27

(A) Disclosure required under the Micro, Small and Medium Enterprises Development Act, 2006 (the Act)

Under the Micro, Small and Medium Enterprises Development Act, 2006, (MSMED) which came into force from 2 October 2006, certain disclosures are required to be made relating to Micro and Small enterprises. There are no Micro, Small and Medium Enterprise to whom the Company owes dues which were outstanding at the balance sheet date. The above information regarding Micro, Small and Medium Enterprise has been determined to the extent such parties have been identified on the basis of the information available with the Company. This has been relied upon by the Auditors.

Particular	As at	
	March 31, 2023	March 31, 2022
Principal amount remaining unpaid to any supplier as at the year end.	-	2.50
Interest due thereon.	-	-
Amount of interest paid by the Company in terms of section 16 of the Act along with the amount of the payment made to the supplier beyond the appointed day during each accounting year.	-	-
Amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Micro, Small and Medium Enterprises Development Act, 2006.	-	-
Amount of interest accrued and remaining unpaid at the end of the accounting year.	-	-

(B) Trade payable ageing schedule

As at March 31, 2023

Particular	Outstanding for following periods from due date of payment				Total
	Less than 1 yr.	1-2 yrs.	2-3 yrs	More than 3 yrs.	
MSME	-	-	-	-	-
Others	997.56	29.33	5.76	12.67	1,045.32
Disputed dues- MSME	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-
Unbilled dues	-	-	-	-	-
Total	997.56	29.33	5.76	12.67	1,045.32

As at March 31, 2022

Particular	Outstanding for following periods from due date of payment				Total
	Less than 1 yr.	1-2 yrs.	2-3 yrs	More than 3 yrs.	
MSME	2.50	-	-	-	2.50
Others	749.57	5.31	2.80	9.09	766.77
Disputed dues- MSME	-	-	-	-	-
Disputed dues- Others	-	-	-	-	-
Unbilled dues	-	-	-	-	-
Total	752.07	5.31	2.80	9.09	769.27



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

8) Other current liabilities

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
Interest accrued but not due on borrowings	6.50	2.99
Advance from customers	96.82	23.62
Security deposit	12.50	12.50
Payables for expenses	48.46	82.16
Employees related dues payables	40.30	48.42
Statutory liabilities	79.78	58.97
Total	284.36	228.66

9) Short - term provisions

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
Provision for employee benefits		
Gratuity (Refer Note 29)	35.72	32.03
Leave encashment (Refer Note 29)	7.44	5.83
Others		
Provision for tax (Net of Advance tax and TDS)	27.43	29.62
Total	70.59	67.48



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

10 : Property, plant & equipment

(Amount in lakhs)

Description	GROSS BLOCK				DEPRECIATION				NET BLOCK		
	As at April 01, 2022	Additions	Deletion	As at March 31, 2023	As at April 01, 2022	Adjustments	For the year	Deduction during the year	As at March 31, 2023	As at March 31, 2023	As at March 31, 2022
Tangible Assets											
Diagnostic Equipments	2,175.37	925.59	-	3,100.96	475.42	-	195.67	-	671.09	2,429.87	1,699.95
Computers	45.14	2.73	-	47.87	39.33	-	2.44	-	41.77	6.10	5.81
Motor Car	150.91	86.34	22.21	215.04	78.01	-	17.41	18.05	77.37	137.67	72.90
Office Equipments	23.65	3.25	-	26.90	18.00	-	1.92	-	19.92	6.98	5.65
Air Conditioner	9.21	-	-	9.21	8.20	-	0.33	-	8.53	0.68	1.01
Furniture and Fixture	12.71	-	-	12.71	9.60	-	0.53	-	10.13	2.58	3.10
Total	2,416.98	1,017.91	22.21	3,412.69	628.56	-	218.30	18.05	828.81	2,583.88	1,788.42
Previous Year	1,795.98	621.01	-	2,416.98	477.12	-	151.44	-	628.56	1,788.42	1,318.85



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

11) Non current investments (Valued at Cost)

(Amount in lakhs)

Particulars	As at				
	March 31, 2023		March 31, 2022		
	No. of Shares	Amount	Amount	No. of Shares	Amount
Long Term - Non Trade - Unquoted Equity Shares					
Parijat Shipping & Finale Ltd. of Rs.10/-each fully paid up	8,78,520		19.35	8,78,520	19.35
Long Term - Non Trade - Quoted Equity Shares					
Sarvamangal Mercantile Co Ltd. of Rs.10/-each fully paid up	18,000	90,000		18,000	
Less : Provision in diminution in value of Investment		90,000	-		-
Total			19.35		19.35

Aggregate amount of Quoted Investments	0.90	0.90
Aggregate Market Value of Quoted Investments	9.00	9.00
Aggregate amount of Unquoted Investments	19.35	19.35
Aggregate Provision for Diminution in value of Investments	0.90	0.90

12) Deferred tax assets / (liabilities) (net)

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
Deferred Tax Liabilities		
Depreciation on Property, plant and equipment	(105.99)	(77.84)
Deferred Tax Assets		
Post Employment Benefits and Provision for Diminution in value of Investments	41.27	41.43
Others	-	110.52
Deferred tax assets / (liabilities) (net)	(64.72)	74.11

13) Other Non-current assets

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
Unsecured, considered good		
Security deposit	403.97	403.97
Other assets	0.14	0.62
Total	404.11	404.59

14) Inventories

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
(Valued at lower of cost and net realisable value)		
Stock-in-trade		
Reagent	448.99	395.05
Medical Equipments	297.65	368.88
Spares	169.91	186.18
Shares	4.14	4.14
Total	920.69	954.25



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

15) Trade receivables

(Amount in lakhs)

Particulars	As at	
	March 31, 2023	March 31, 2022
(Unsecured, Considered Good)	1,850.87	940.72
Total	1,850.87	940.72

Trade receivables ageing schedule

As at March 31, 2023

Particular	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 yrs.	2-3 yrs	More than 3 yrs.	
Undisputed - Considered Good	1,739.81	55.21	29.69	8.12	18.04	1,850.87
Undisputed - Considered Doubtful	-	-	-	-	-	-
Disputed - Considered Good	-	-	-	-	-	-
Disputed - Considered Doubtful	-	-	-	-	-	-
Total	1,739.81	55.21	29.69	8.12	18.04	1,850.87

As at March 31, 2022

Particular	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 yrs.	2-3 yrs	More than 3 yrs.	
Undisputed - Considered Good	840.94	25.00	19.34	41.33	14.11	940.72
Undisputed - Considered Doubtful	-	-	-	-	-	-
Disputed - Considered Good	-	-	-	-	-	-
Disputed - Considered Doubtful	-	-	-	-	-	-
Total	840.94	25.00	19.34	41.33	14.11	940.72



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

16) Cash and bank balances

Particulars	(Amount in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Cash & Cash Equivalents		
Cash on Hand	3.74	3.77
Balances with Banks		
in Current Accounts	16.72	18.41
Fixed Deposits with Banks (Maturity of less than 3 months)	180.00	-
Other Bank Balances		
Fixed deposits with Banks (Maturity of more than 3 months & less than 12 months)	50.55	-
Fixed deposits with Banks (Maturity of more than 12 months)	320.00	-
Fixed deposits with Banks, marked as a margin money against the guarantees and letter of credit	212.00	612.55
Total	783.01	634.73

17) Short-term loans and advances

Particulars	(Amount in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Deposits	238.81	253.37
Other loans & advances	112.30	15.96
Total	351.11	269.33

18) Other current assets

Particulars	(Amount in lakhs)	
	As at	
	March 31, 2023	March 31, 2022
Interest accrued but not due	55.29	28.29
Prepaid expenses	14.88	10.26
Advances to creditors	147.82	9.38
Balance with Government Authorities	30.19	45.80
Advances recoverable in cash or kind	5.82	6.71
Total	254.00	100.44



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

19) Revenue from operations

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Sales of product	6,930.72	5,317.64
Other operating income		
Service Charges	126.24	68.34
Commission	-	0.90
Total	7,056.96	5,386.88

20) Other Income

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Interest	44.12	25.28
Royalty	9.00	12.00
Net gain on foreign currency transaction and translation	-	20.44
Sundry balances w/back	-	0.16
Profit on Sale of Fixed Assets	1.54	-
Bad debts recovered	2.37	2.80
Total	67.76	60.68

21) Purchase of stock-in-trade

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Reagents, spares and consumables	2,539.25	1,980.31
Medical Equipments	860.10	1,019.57
Total	3,399.35	2,999.88

22) Changes in Inventory of Stock-in-Trade

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Opening Stock	954.25	816.44
Less : Closing Stock	920.69	954.25
Total	33.56	(137.81)

23) Employee benefit expense

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Salaries, wages and bonus	785.88	693.64
Contribution to provident and other Fund	38.45	36.91
Staff welfare expense	37.44	29.98
Total	861.77	760.53



KOPRAN LABORATORIES LIMITED
NOTES FORMING PART OF THE FINANCIAL STATEMENTS

24) Finance cost

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Interest expense	89.97	79.93
Loan processing charges	7.43	4.34
Bank charges	29.70	31.44
Total	127.10	115.71

25) Other Expenses

(Amount in lakhs)

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Rent, Rates & Taxes	63.80	81.24
Auditor's Remuneration (Refer Note 'A' below)	2.30	2.30
Advertisement	0.48	2.20
CSR Expenses	13.70	12.73
General & Labour Charges	11.30	10.89
Repairs & Maintenance	120.00	82.97
Electricity Charges	10.35	10.39
Conference and Training Expenses	60.41	7.25
Commission on Sales	133.06	93.04
Sales Promotion Expenses	24.47	3.15
Packing, Freight and Forwarding	114.26	77.82
Printing and Stationery	6.35	4.39
Postage, Telegram and Telephone	10.22	14.97
Travelling and Conveyance	336.65	214.36
Legal and Professional Fees	120.08	109.31
Installation Charges	23.82	10.14
Bad debts	0.01	40.04
GST Dues	1.64	-
License Fees	0.06	9.67
Net loss on foreign currency transaction and translation	10.23	-
Sundry Balance W/off	0.01	11.03
Miscellaneous Expenses	21.30	19.48
Total	1,084.50	817.36
(A) Auditor's Remuneration		
For statutory audit	1.50	1.50
For Tax audit	0.80	0.80
Total	2.30	2.30

26) Earnings per Equity Share

Particulars	Year Ended	
	March 31, 2023	March 31, 2022
Number of Equity Shares	20,00,000	20,00,000
Weighted average number of Equity Shares	20,00,000	20,00,000
Face Value per share (Rs.)	10	10
Profit after tax available to Equity Shareholders (Rs. In lakhs)	926.31	601.13
Basic and Diluted Earning Per Share (Rs.)	46.32	30.06



1. CORPORATE INFORMATION

Kopran Laboratories Limited ('the Company') is a public limited company domiciled and incorporated in India having its registered office at Parijat House, 1076, DR. E. Moses Road, Worli, Mumbai - 400 018, India. The company is carrying on the business of trading of medical equipment, reagents and consumables, provides laboratory automation solutions and delivers projects in hospital infrastructure.

The financial statements for the period April 01, 2022 to March 31, 2023, have been approved and authorized for issue by the Board of Directors of the Company in their meeting held on September 04, 2023.

2. SIGNIFICANT ACCOUNTING POLICIES

2.1. Basis of Preparation of Financial Statements

These financial statements are prepared in accordance with Indian Generally Accepted Accounting Principles (GAAP) under the historical cost convention on the accrual basis, Pursuant to Section 133 of the Companies Act, 2013 ('the Act') read with Rule 7 of the Companies (Accounts) Rules, 2014. Accounting policies have been consistently applied.

The presentation is based on the Schedule III of the Companies Act, 2013. All assets and liabilities are classified into current and non-current generally based on the criteria of realization / settlement within twelve months period from the balance sheet date.

2.2 Use of Estimates

The preparation of the financial statements in conformity with GAAP requires the management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent assets and liabilities as at the date of the financial statements and reported amounts of income and expenses during the period. Examples of such estimates include provisions for doubtful debts, future obligations under employee retirement benefit plans, income taxes, post-sales customer support and the useful lives of Property, Plant and Equipment and intangible assets. The difference between the actual result and estimate are recognised in the period in which results are know or materialised.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2.3. Revenue Recognition

- i. Sale comprises of sale of goods net of trade discounts. It is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured and is recognized on accrual basis.
- ii. Service charges and Commission income is recognized as and when accrued in terms of the agreement with the customer over the period of the contract.
- iii. Interest income is recognized on time proportion basis taking into account the amount invested and the rate of interest.

2.4. Property, Plant and Equipment and Depreciation

- i. All Property, Plant and Equipment are stated at cost of acquisition or construction less accumulated depreciation and impairment loss, if any.
- ii. Effective 1st April 2014, the Company depreciates its Property, Plant and Equipment over the useful life as per Schedule II of The Companies Act, 2013 except in case of Building Improvements which are depreciated over the estimated useful life of 10 years.
- iii. Depreciation on Property, Plant and Equipment added/disposed off during the period is provided for on pro-rata basis with reference to date of installation /put to use/ date of sale.
- iv. Intangible assets are recognized only if it is probable that the future economic benefits that are attributable to the asset will flow to the enterprise and the cost of the asset can be measured reliably. The intangible assets are recorded at cost and are carried at cost less accumulated amortization.
- v. Capital Work in Progress is stated at cost, comprising of direct Cost, attributable borrowing cost and related incidental expenditure. All expenses incurred for acquiring, erecting and commissioning of fixed assets and incidental expenditure incurred during construction of the projects are shown under Capital Work in Progress. The advances given for acquiring fixed assets are shown under Capital Work in Progress.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2.5. Investments

- i. Investments are classified into Current Investment and Non-Current Investments.
- ii. Non-Current Investments are carried at cost. Provision for diminution is made only if, in the opinion of the management, such a decline is other than temporary.
- iii. Quoted Investments are valued at cost or market value whichever is lower. Unquoted investments are stated at cost. The decline in the value of the unquoted investments, other than temporary, is provided for. Cost is inclusive of brokerage, fees and duties but excludes Securities Transaction Tax, if any.

2.6. Inventories

Inventories are valued at cost or net realisable value whichever is lower. Cost of inventories comprises all costs of purchase and other costs incurred in bringing the inventories to their present location and condition.

2.7. Impairment of Assets

The Property, Plant and Equipment are reviewed for impairment at each balance sheet date. In case of any such indication, the recoverable amount of these assets is determined and if such recoverable amount of the asset or cash generating unit to which the assets belongs is less than its carrying amount, the impairment loss is recognised by writing down such assets to their recoverable amount. An impairment loss is reversed if there is change in the recoverable amount and such loss either no longer exists or has decreased.

2.8. Foreign Currency Transactions

- i. Foreign currency transactions are recorded at the exchange rate prevailing on the date of transaction. Exchange difference arising on settlement/conversion is adjusted to Statement of Profit & Loss.
- ii. Monetary assets and liabilities denominated in foreign currencies as at the Balance Sheet date are translated at the closing exchange rates on that date; the resultant exchange differences are recognized in the Statement of Profit and Loss.



2.9. Employee Benefits

1. Short Term Employee Benefits

All employee benefits payable wholly within twelve months of rendering the service are classified as short-term employee benefits. Undiscounted value of benefits such as salaries and bonus are recognized in the period in which the employee renders the related service

2. Defined contribution plans

All employees of the Company are entitled to receive benefits under the Provident Fund, which is a defined contribution plan. Both the employees and the employer make monthly contributions to the plan at a predetermined rate (presently 12%) of the employees' basic salary. These contributions are made to the fund administered and managed by the Government of India.

The Company's contributions to Provident Fund and employees' state insurance schemes are expensed. The Company has no further obligations under these plans beyond its monthly contributions.

3. Defined benefit plans

i. Gratuity

Liability in respect of gratuity is determined using the projected unit credit method with actuarial valuations as on the balance sheet date and gains/losses are recognized immediately in the Statement of Profit & Loss.

ii. Leave Encashment

Liability in respect of leave encashment is determined using the projected unit credit method with actuarial valuations as on the balance sheet date and gains/losses are recognized immediately in the Statement of Profit & Loss.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2.10. Borrowing Cost

Borrowing costs that are directly attributable to the acquisition, construction or production of qualifying assets till the time they are ready for intended use are capitalized as part of cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. Other borrowing costs are recognized as an expense in the period in which they are incurred.

2.11. Earnings per Share

In accordance with the Accounting Standard (AS) – 20 “Earnings Per Share” issued by the Institute of Chartered Accountants of India, basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all potential dilutive equity shares, except where result would be anti-dilutive.

2.12. Income Tax

Provision for current tax is made on the basis of estimated taxable income for the current accounting year in accordance with the Income Tax Act, 1961. Deferred tax assets and liabilities are recognized for the future tax consequences of timing differences, subject to the consideration of prudence. Deferred tax assets and liabilities are measured using the tax rates enacted or substantively enacted by the balance sheet date. The carrying amount of deferred tax asset / liability is reviewed at each balance sheet date.

2.13. Prior Period Items

Prior period expenses/income is accounted under the respective heads. Material items, if any, are disclosed separately by way of a note.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

2.14. Provisions & Contingent Liabilities

The Company creates a provision when there is a present obligation as a result of an obligating event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.

2.15. Other Accounting Policies

These are consistent with the generally accepted accounting practices.

27. Contingent Liabilities not provided for:

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
Bank Guarantees	666.20	431.74
Sales Tax*	-	204.36

*The Company has disputed demand raised by the sales tax authorities for which the Company had filed an appeal before the appropriate authority and has received favourable order, hence the company has removed it from the contingent liability.



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS****28. Accounting Ratios with calculations:**

Particulars	Formula	2022-23	2021-22	% Change during the Year	Reason for Change
1. Current Ratio	Current Assets /Current Liabilities	1.77	2.13	-16.64%	-
2. Debt-Equity Ratio	Total Debt /Shareholders Equity	0.42	0.42	0.82%	-
3. Debt Service Coverage Ratio	Earnings available for Debt Service /Debt Service	2.08	2.10	-0.77%	-
4. Return on Equity	Net Profit after tax /Average Shareholder's Equity	0.27	0.22	20.03%	-
5. Inventory Turnover Ratio	Cost of Goods Sold /Average Inventory	3.66	3.23	13.28%	-
6. Trade Receivables Turnover Ratio	Net Credit Sales /Average Accounts Receivable	5.06	6.17	-18.01%	-
7. Trade Payables Turnover Ratio	Net Credit Purchases /Average Trade Payables	3.75	4.35	-13.92%	-
8. Net Capital Turnover Ratio	Net Sales / Working Capital	3.90	3.51	11.01%	-
9. Net Profit Ratio	Net Profit/Net Sales	0.13	0.11	17.63%	-
10. Return on Capital Employed	EBIT/Capital Employed	0.27	0.22	20.73%	-
11. Return on Investment	Income generated from investments / Average Investments	0.04	0.00	100.00%	Not applicable in FY 21-22

29. During the year the company have imported good worth the following on CIF value:

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
Reagent	654.53	574.92
Medical equipment	248.68	709.55
Spares and consumables	100.47	79.32
Total	1,003.68	1,363.79

30. In the opinion of the Board, all current assets, loans & advances and other receivables are approximately of the value stated, if realised in the ordinary course of business.

KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS****31. Employee Benefits:****Gratuity (Unfunded)**

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
i) Change in Benefit Obligation		
Projected Benefit Obligations (PBO) at the beginning of the year	115.70	110.61
Interest Cost	8.41	7.60
Service Cost	6.30	6.61
Pat Service Cost		
Benefits Paid by the Employer	(9.58)	(7.77)
Actuarial (gain)/loss on obligations due to change in assumptions	(11.38)	(1.35)
Projected Benefit Obligations (PBO) at the end of the year	109.45	115.70
ii) Fair Value of Plan Assets		
Fair Value of Plan Assets at beginning of the year	-	-
Expected Return on Plan Assets	-	-
Contributions	-	-
Benefits paid	-	-
Gain / (loss) on Plan Assets	-	-
Fair Value of Plan Assets at the end of the year		
iii) Change in Plan Assets		
Fair Value of Plan Assets at the beginning of the year	-	-
Actual-return on Plan Assets	-	-
Contributions	-	-
Benefits paid	-	-
Fair Value of Plan Assets at the end of the year		
iv) Funded Status	(109.45)	(115.70)
v) Limits of Corridor not considered since total actuarial gain/loss is being recognised		
Actuarial (gain)/loss for the year – Obligation	(11.38)	(1.35)
Actuarial (gain)/loss for the year – Plan Assets	-	-
Sub-Total	(11.38)	(1.35)
Actuarial (gain)/loss recognised	(11.38)	(1.35)
Unrecognised actuarial (gains)/losses at the end of the year	-	-
vi) The Amounts to be recognised in Balance Sheet and Income Statement and the related analysis		
Present Value of Obligation	109.45	115.70
Fair Value of Plan Assets	-	-




KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
Deficit	109.45	115.70
Unrecognised Actuarial gains(losses)	-	-
Unrecognised Transitional Liability	-	-
Net Liability Recognised in Balance Sheet	109.45	115.70
vii) Net Periodic Cost		
Current Service Cost	6.30	6.61
Interest Cost	8.41	7.60
Expected Return on Plan Assets	-	-
Net Actuarial (gain)/ loss recognised in the year	(11.38)	(1.35)
Past Service Cost	-	-
Expenses Recognised in the Statement of Profit or Loss	3.33	12.86
viii) Movements in the liability recognised in the Balance Sheet		
Opening Net Liability	115.70	110.61
Expense as above	3.33	12.86
Benefit paid	(9.58)	(7.77)
Closing Net Liability	109.45	115.70
ix) Assumptions		
Discount Rate	7.49%	7.27%
Rate of increase in Compensation levels	6.00%	6.00%
x) Rate of Employee Turnover	1.00%	1.00%

Compensated Absences (Unfunded)

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
i) Change in Benefit Obligation		
Projected Benefit Obligations (PBO) at the beginning of the year	48.93	48.72
Interest Cost	3.56	3.35
Service Cost	1.01	1.21
Benefits Paid	(2.24)	(1.41)
Actuarial (gain) / loss on obligations	2.39	(2.94)
Projected Benefit Obligations (PBO) at the end of the year	53.65	48.93
ii) Fair Value of Plan Assets		
Fair Value of Plan Assets at the beginning of the year	-	-
Expected Return on Plan Assets	-	-
Contributions		



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
Benefits paid	-	-
Gain / (loss) on Plan Assets	-	-
Fair Value of Plan Assets at the end of the year	-	-
iii) Change in Plan Assets	-	-
Fair Value of Plan Assets at the beginning of the year	-	-
Actual return on Plan Assets		
Contributions	-	-
Benefits paid	-	-
Fair Value of Plan Assets at the end of the year	-	-
iv) Funded Status	-	-
v) Limits of Corridor not considered since total actuarial gain/loss is being recognised as on 31.03.21		
Actuarial (gain)/loss for the year – Obligation	2.39	(2.94)
Actuarial (gain)/loss for the year – Plan Assets	-	-
Sub-Total	2.39	(2.94)
Actuarial loss recognised	2.39	(2.94)
Unrecognised actuarial (gains)/ losses at the end of the year	-	-
vi) The Amounts to be recognised in Balance Sheet and Income Statement and the related analysis		
Present Value of Obligation	53.65	48.93
Fair Value of Plan Assets	-	-
Deficit	53.65	48.93
Unrecognised Actuarial gains(losses)	-	-
Unrecognised Transitional Liability	-	-
Net Liability Recognised in the Balance Sheet	53.65	48.93
vii) Net Periodic Cost		
Current Service Cost	1.01	1.21
Net Interest Cost	3.56	3.35
Expected Return on Plan Assets	-	-
Net Actuarial (gain)/loss recognised in the year	2.39	(2.94)
Expenses Recognised in the Statement of Profit or Loss	6.96	1.61
viii) Movements in the liability recognised in the Balance Sheet		
Opening Net Liability	48.93	48.72
Expense as above	6.96	1.61
Benefit paid	(2.24)	(1.41)
Closing Net Liability	53.65	48.93



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

Particulars	For the year ended	For the year ended
	March 31, 2023 (Rs. in lakhs)	March 31, 2022 (Rs. in lakhs)
ix) Assumptions		
Discount Rate	7.49%	7.27%
Rate of increase in Compensation levels	6.00%	6.00%
x) Rate of Employee Turnover	1.00%	1.00%

32. Disclosure of related parties/related party transactions pursuant to Accounting Standard (AS) 18 "Related Party Disclosures"

a) List of related parties

Sr. No.	Nature of Relationship	Name of Related Parties
I	Key Management Personnel	Mr. Varun Somani
		Mr. Adarsh Somani
II	Relative of Key Management Personnel (KMP)	Mr. Surendra Somani
		Mrs. Namrata Somani
		Mrs. Nupur Somani
		Mrs. Vandana Somani
		Mrs. Mridula Somani
III	Enterprise having Significant Influence	Sarvamangal Mercantile Co Ltd
IV	Enterprise over which either KMP or their relative have Significant Influence	Kopran Limited
		Oricon Enterprises Limited

b) Transactions with Related Parties

Sr. No.	Name of Related party	Transaction during the year	March 31, 2023 (Rs. in Lakhs)	March 31, 2022 (Rs. in Lakhs)
1	Mr. Varun Somani	Salary & Perks	113.94	88.50
		Commission	46.00	25.00
		Loan Taken	100.00	35.00
		Loan Repaid	108.00	8.00
2	Mr. Adarsh Somani	Loan Taken	NIL	NIL
		Loan Repaid	100.00	45.00
3	Mrs. Namrata Somani	Loan Taken	NIL	7.50
		Loan Repaid	5.00	5.00
4	Kopran Limited	Exp. Charges Paid	0.16	0.16



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS****Outstanding Balances**

Sr. No.	Name of Related party	Outstanding Balances	March 31, 2023 (Rs. in Lakhs)	March 31, 2022 (Rs. in Lakhs)
1	Mr.Varun Somani	Loan Outstanding	124.00	132.00
2	Mr.Adarsh Somani	Loan Outstanding	14.50	114.50
3	Mrs. Namrata Somani	Loan Outstanding	181.50	186.50
4	Oricon Enterprises Ltd.	Payable	3.59	3.84

33. Disclosures pursuant to Accounting Standard (AS) 17 "Segment Reporting

The company operates in a single business segment viz. business of trading of medical equipment and chemical knowns as 'reagents' products and accordingly there is no reportable business or geographical segments as prescribed Under Accounting Standard 17 "Segment Reporting".

34. Expenditure incurred in foreign currency

Particulars	For the year ended March 31, 2023 (Rs. in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
Travelling and Conveyance	63.20	27.41
Conference and training expenses	9.85	-

35. Corporate Social Responsibility

As per section 135 of the Companies Act, 2013, amount required to be spent by the Company during the year ended March 31, 2023 and March 31, 2022 is Rs. 13.68 lakhs and Rs. 12.73 lakhs, respectively, computed at 2% of its average net profit for the immediately preceding three financial years, on Corporate Social Responsibility (CSR). The Company incurred an amount of Rs. 13.70 lakhs and Rs. 12.73 lakhs during the year ended March 31, 2023 and March 31, 2022, respectively, towards CSR expenditure for purposes other than construction / acquisition of any asset.

Particulars	For the year ended March 31, 2023 (Rs.in lakhs)	For the year ended March 31, 2022 (Rs. in lakhs)
i) Amount required to be spent by the Company during the year	13.68	12.73
ii) Amount of expenditure incurred	13.70	12.73



KOPRAN LABORATORIES LTD.**NOTES FORMING PART OF THE FINANCIAL STATEMENTS**

iii) Shortfall at the end of the year	NIL	NIL
iv) Total of Previous years Shortfall	NIL	NIL
v) Reason for Shortfall	NIL	NIL
vi) Nature of CSR Activities	Empowerment of the underprivileged communities in rural Odisha through good quality education	Construction of new building and helping ashram inmates including homeless, old age people
vii) Details of related party transactions e.g. Contribution to a trust controlled by the Company in relation to CSR expenditure as per relevant Accounting Standard	NIL	NIL
viii) Where a provision is made with respect to a liability incurred by entering into a contractual obligation, the movements in the provision during the year should be shown	NIL	NIL

36. Details of Loans given, covered u/s 186 (4) of the Companies Act, 2013

Particulars	For the year ended	For the year ended
	March 31, 2023	March 31, 2022
	(Rs. in lakhs)	(Rs. in lakhs)
Loans and advances in the nature of loans		
Pankaj Trading Corporation		
Loans given during the year	150.00	-
Balance as at the year end	100.00	-
Maximum amount outstanding at any time during the year	150.00	-
Purpose: To be used for principal business activity of the borrower		

37. Other Disclosures

- There were no litigations and proceedings pending as at March 31, 2023.
- The Company did not have any outstanding long - term contracts including derivative contracts as at March 31, 2023.
- There is no amount required to be transferred to the Investor Education and Protection Fund by the Company.

38. Additional Regulatory Information

- There are no immovable properties held in the name of the Company.
- As the Company have not revalued its Property, Plant and Equipment, accordingly compliance with Rule 2 of Companies (Registered Valuers and Valuation) Rules, 2017 does not arise.



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

- iii. The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties, as defined under the Companies Act, 2013, either severally or jointly with any other person that repayable on demand or without specifying any term or period of repayment.
- iv. The Company does not have any intangible assets under development.
- v. The Company does not have any Benami Property under the Benami Transactions (Prohibition) Act, 1988.
- vi. The Company has availed borrowings from banks or financial institutions on the basis of security of stock and book debts. The Company has filed quarterly returns or statement Company with banks or financial institution and there are no material discrepancies observed between the quarterly returns or statement filed and the books of account.
- vii. The Company has not been declared as wilful defaulter by any bank or financial institutions or government or government authority.
- viii. The Company does not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- ix. The Company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 in the current year.
- x. The Company does not have any identified transaction with struck off company during the year.
- xi. The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.
- xii. The Company has not advanced or loaned or invested funds to any other person(s) or entity, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries



KOPRAN LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS


- xiii. The Company has not received any fund from any person or entity, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- xiv. The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income-tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income-tax Act, 1961
- xv. The Company does not have any subsidiary as at the balance sheet date, accordingly compliance with section 2(89) of the Companies Act read with Companies (Restriction on number of layers) Rules, 2017 does not arise.
39. Previous year's figures are regrouped and rearranged wherever considered necessary to correspond with the current year's classification / disclosure.

As per our report of even date

For KHANDELWAL JAIN & CO

Chartered Accountants

Firm Registration No. - 105049W


S.S. Shah

PARTNER

Membership No. 033632




For and on behalf of Board of Directors



VARUN SOMANI
MANAGING DIRECTOR

DIN No. 00015384



NAMRATA SOMANI
DIRECTOR

DIN No. 07095595

Place: Mumbai

Date : 04/09/2023